跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 255 条关于
“LG-UTUC”
全部
255
临床试验
82
药物
104
机构
6
资讯
63
去年
JELMYTO Demonstrates Durable Response in Low-Grade Upper Tract Urothelial Cancer
2年前
UroGen Pharma's UGN-102 Shows Promise in Bladder Cancer Treatment
去年
ImPact Biotech to Present Phase 3 Data on Padeliporfin for Low-Grade UTUC at EMUC 2024
去年
UroGen's UGN-102 Receives FDA Acceptance for Bladder Cancer Treatment
3个月前
UroGen Pharma Settles Patent Litigation with Teva, Secures JELMYTO Protection Until 2030
10个月前
ImPact Biotech Reports 73% Complete Response Rate in Phase 3 ENLIGHTED Trial of Padeliporfin VTP for Low-Grade UTUC
9个月前
ImPact Biotech Reports 70% Complete Response Rate in Phase 3 ENLIGHTED Trial of Padeliporfin VTP for Low-Grade Upper Tract Urothelial Cancer
去年
UroGen's UGN-102 Shows Promise for Non-Muscle Invasive Bladder Cancer
去年
Ferring Advances Nadofaragene Firadenovec Clinical Program in Urothelial Cancers
9天前
Tyra's Oral FGFR3 Inhibitor Dabogratinib Hits 100% ORR in Single-Lesion NMIBC, But Phase 2 Data Miss Street Bar
第 1 页,共 7 页
上一页
下一页